Physician profile
Michaela Besold
NPI 1184619991
$2,329.55
in general payments reported to CMS, 2019-2025
27 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2021: $192 · 2022: $199 · 2023: $387 · 2024: $690 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.79 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $275.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $194.60 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $176.97 | 2022-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $165.92 | 2019-2023 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $157.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $151.34 | 2019-2025 | |
| Pfizer INC. | $142.82 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $137.42 | 2021 | |
| Abbvie INC. | $77.11 | 2021-2024 | |
| Astellas Pharma US INC | $71.58 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $60.91 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $43.48 | 2025 | Auvelity |
| Abbott Laboratories | $41.26 | 2024 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $35.92 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.14 | 2023-2025 | Seglentis, Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2023 | Jardiance |
| Dexcom, INC. | $27.58 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $23.46 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.14 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.87 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $15.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2021 | |
| Mission Pharmacal Company | $13.82 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $13.48 | 2022 | |
| Dynavax Technologies Corporation | $13.15 | 2024 | Heplisav-B |
| Shire North American Group INC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Besold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.